Detalles de la búsqueda
1.
Discovery of thiazolobenzoxepin PI3-kinase inhibitors that spare the PI3-kinase ß isoform.
Bioorg Med Chem Lett
; 23(9): 2606-13, 2013 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23540645
2.
Preclinical assessment of the absorption and disposition of the phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor GDC-0980 and prediction of its pharmacokinetics and efficacy in human.
Drug Metab Dispos
; 40(9): 1785-96, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22696419
3.
Structure-based design of thienobenzoxepin inhibitors of PI3-kinase.
Bioorg Med Chem Lett
; 21(13): 4054-8, 2011 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21636270
4.
Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
Drug Metab Dispos
; 38(9): 1436-42, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20538720
5.
Discovery of dihydrothieno- and dihydrofuropyrimidines as potent pan Akt inhibitors.
Bioorg Med Chem Lett
; 20(23): 7037-41, 2010 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20971641
6.
Structure-based optimization of pyrazolo-pyrimidine and -pyridine inhibitors of PI3-kinase.
Bioorg Med Chem Lett
; 20(20): 6048-51, 2010 Oct 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20822905
7.
The Rational Design of Selective Benzoxazepin Inhibitors of the α-Isoform of Phosphoinositide 3-Kinase Culminating in the Identification of (S)-2-((2-(1-Isopropyl-1H-1,2,4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)oxy)propanamide (GDC-0326).
J Med Chem
; 59(3): 985-1002, 2016 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-26741947
8.
Discovery of 2-{3-[2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide (GDC-0032): a ß-sparing phosphoinositide 3-kinase inhibitor with high unbound exposure and robust in vivo antitumor activity.
J Med Chem
; 56(11): 4597-610, 2013 Jun 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-23662903
9.
GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
Clin Cancer Res
; 18(14): 3901-11, 2012 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22586300
10.
Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer.
J Med Chem
; 54(21): 7579-87, 2011 Nov 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-21981714
11.
GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway.
Mol Cancer Ther
; 10(12): 2426-36, 2011 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-21998291
12.
Nuclear phospho-Akt increase predicts synergy of PI3K inhibition and doxorubicin in breast and ovarian cancer.
Sci Transl Med
; 2(48): 48ra66, 2010 Sep 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-20826841
13.
Isoform-specific phosphoinositide 3-kinase inhibitors exert distinct effects in solid tumors.
Cancer Res
; 70(3): 1164-72, 2010 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-20103642
14.
Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
Clin Cancer Res
; 16(14): 3670-83, 2010 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-20453058
15.
Discovery of (thienopyrimidin-2-yl)aminopyrimidines as potent, selective, and orally available pan-PI3-kinase and dual pan-PI3-kinase/mTOR inhibitors for the treatment of cancer.
J Med Chem
; 53(3): 1086-97, 2010 Feb 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-20050669
16.
Anti-tumor efficacy of human angiostatin using liver-mediated adeno-associated virus gene therapy.
Mol Ther
; 9(1): 56-66, 2004 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-14741778
Resultados
1 -
16
de 16
1
Próxima >
>>